Epigenetic regulation of AURKA by miR-4715-3p in upper gastrointestinal cancers.
3' Untranslated Regions
Antineoplastic Agents
/ pharmacology
Aurora Kinase A
/ genetics
Cisplatin
/ pharmacology
DNA Methylation
Epigenesis, Genetic
Gastrointestinal Neoplasms
/ genetics
Gene Expression Regulation, Neoplastic
Humans
Kaplan-Meier Estimate
MicroRNAs
/ genetics
Phospholipid Hydroperoxide Glutathione Peroxidase
/ genetics
Polyploidy
Stomach Neoplasms
/ drug therapy
Upper Gastrointestinal Tract
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 11 2019
18 11 2019
Historique:
received:
17
07
2019
accepted:
29
10
2019
entrez:
20
11
2019
pubmed:
20
11
2019
medline:
15
12
2020
Statut:
epublish
Résumé
Aurora kinase A (AURKA) is frequently overexpressed in several cancers. miRNA sequencing and bioinformatics analysis indicated significant downregulation of miR-4715-3p. We found that miR-4715-3p has putative binding sites on the 3UTR region of AURKA. Upper gastrointestinal adenocarcinoma (UGC) tissue samples and cell models demonstrated significant overexpression of AURKA with downregulation of miR-4715-3p. Luciferase reporter assays confirmed binding of miR-4715-3p on the 3UTR region of AURKA. miR-4715-3p mediated a reduction in AURKA levels leading to G2/M delay, chromosomal polyploidy, and cell death. We also detected a remarkable decrease in GPX4, an inhibitor of ferroptosis, with an increase in cleaved PARP and caspase-3. Inhibition of AURKA using siRNA produced similar results, suggesting a possible link between AURKA and GPX4. Analysis of UGC samples and cell models demonstrated increased methylation levels of several CpG nucleotides upstream of miR-4715-3p. 5-Aza-2'-deoxycytidine induced demethylation of several CpG nucleotides, restoring miR-4715-3p expression, leading to downregulation of AURKA. In conclusion, our data identified a novel epigenetic mechanism mediating silencing of miR-4715-3p and induction of AURKA in UGCs. Inhibition of AURKA or reconstitution of miR-4715-3p inhibited GPX4 and induced cell death, suggesting a link between AURKA and ferroptosis.
Identifiants
pubmed: 31740746
doi: 10.1038/s41598-019-53174-6
pii: 10.1038/s41598-019-53174-6
pmc: PMC6861278
doi:
Substances chimiques
3' Untranslated Regions
0
Antineoplastic Agents
0
MicroRNAs
0
Phospholipid Hydroperoxide Glutathione Peroxidase
EC 1.11.1.12
AURKA protein, human
EC 2.7.11.1
Aurora Kinase A
EC 2.7.11.1
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
16970Subventions
Organisme : BLRD VA
ID : I01 BX001179
Pays : United States
Organisme : BLRD VA
ID : IK6 BX003787
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA240139
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA131225
Pays : United States
Références
Neoplasia. 2017 Dec;19(12):1022-1032
pubmed: 29144989
Clin Cancer Res. 2014 Jan 1;20(1):76-86
pubmed: 24240108
Gastroenterology. 2013 Dec;145(6):1312-22.e1-8
pubmed: 23993973
J Pathol Clin Res. 2014 Nov 07;1(1):33-40
pubmed: 27499891
Clin Cancer Res. 2017 Jul 15;23(14):3756-3768
pubmed: 28073841
Cancer Lett. 2006 Oct 28;242(2):273-9
pubmed: 16412566
Curr Genomics. 2010 Nov;11(7):537-61
pubmed: 21532838
Oncogene. 2009 Feb 12;28(6):866-75
pubmed: 19060929
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):13726-13731
pubmed: 27837025
Cell Death Dis. 2016 Jul 21;7:e2307
pubmed: 27441659
Cancer Cell. 2012 Feb 14;21(2):196-211
pubmed: 22340593
Oncotarget. 2016 Aug 2;7(31):49322-49333
pubmed: 27384994
Nature. 2017 Jan 12;541(7636):169-175
pubmed: 28052061
Genom Data. 2015 Nov 27;7:92-3
pubmed: 26981373
Nat Med. 2016 Jul;22(7):744-53
pubmed: 27213815
Clin Cancer Res. 2003 Mar;9(3):991-7
pubmed: 12631597
Oncogenesis. 2017 Feb 20;6(2):e298
pubmed: 28218735
Cancer Res. 2010 Jun 1;70(11):4655-65
pubmed: 20460511
Mol Cancer. 2012 Jan 30;11:5
pubmed: 22289355
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Curr Cancer Drug Targets. 2017;17(4):386-401
pubmed: 27396604
Oncotarget. 2016 May 31;7(22):33152-64
pubmed: 27121204
Cancer. 2013 Feb 15;119(4):904-14
pubmed: 22972611
J Transl Med. 2014 Jul 31;12:200
pubmed: 25082261
Cell. 2014 Jan 16;156(1-2):317-331
pubmed: 24439385
Oncol Rep. 2004 Sep;12(3):593-9
pubmed: 15289843
Sci Rep. 2018 Jun 15;8(1):9227
pubmed: 29907753
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Curr Top Microbiol Immunol. 2017;403:143-170
pubmed: 28204974
Onco Targets Ther. 2015 Dec 07;8:3639-48
pubmed: 26675712
Nat Cell Biol. 2014 Dec;16(12):1180-91
pubmed: 25402683
Theranostics. 2018 Feb 12;8(6):1740-1751
pubmed: 29556353
Mol Oncol. 2017 Aug;11(8):981-995
pubmed: 28417568
Oncol Rep. 2007 May;17(5):1083-8
pubmed: 17390048
Nat Rev Cancer. 2017 Jan 27;17(2):93-115
pubmed: 28127048
Hum Pathol. 2013 Jan;44(1):77-86
pubmed: 22939955
J Transl Med. 2016 May 20;14(1):143
pubmed: 27197967
PLoS One. 2015 Mar 04;10(3):e0117714
pubmed: 25739101
Nat Commun. 2016 Jan 19;7:10180
pubmed: 26782714
Gastroenterology. 2019 Mar;156(4):1127-1139.e8
pubmed: 30502323
J Invest Dermatol. 2017 Jun;137(6):1297-1310
pubmed: 28188776
Cancer Res. 1999 May 1;59(9):2041-4
pubmed: 10232583
Gut. 2009 Jan;58(1):5-15
pubmed: 18664505
J Pathol Transl Med. 2017 Jan;51(1):32-39
pubmed: 28013532
Cell Rep. 2017 Aug 15;20(7):1692-1704
pubmed: 28813679
Cancer Res. 2008 Nov 1;68(21):8998-9004
pubmed: 18974145
Nature. 2019 Aug;572(7769):402-406
pubmed: 31341276
Epigenetics. 2014 Jun;9(6):910-7
pubmed: 24686393
IUBMB Life. 2016 Aug;68(8):634-44
pubmed: 27270838
Mol Cancer. 2015 May 20;14:106
pubmed: 25987188
Int J Biochem Cell Biol. 2018 May;98:89-92
pubmed: 29544896
EMBO J. 1998 Jun 1;17(11):3052-65
pubmed: 9606188
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Blood. 2010 Jun 24;115(25):5202-13
pubmed: 20382844
J Natl Cancer Inst. 2000 Apr 5;92(7):569-73
pubmed: 10749913
Nat Rev Cancer. 2006 Nov;6(11):857-66
pubmed: 17060945
Sci Rep. 2017 Jan 19;7:40729
pubmed: 28102292
Int J Oncol. 2019 Jan;54(1):53-64
pubmed: 30387838
J Clin Invest. 2013 Jun;123(6):2502-8
pubmed: 23676460